摘要
临床数据交换标准协会(CDISC)制定了一系列规范临床和非临床研究数据的基础标准,以合理化数据的收集、管理、分析、报告和提交流程。目前,多国药监部门、制药企业及学术单位普遍采用CDISC标准。为加速对公共健康有重大影响的疾病领域相关临床研究数据标准的开发,自2012年起,CDISC开发治疗领域(therapeutic areas,TA)数据标准,目前已发布20余个TA标准。相较于CDISC基础标准,国内用户对TA标准的熟知度偏低,本文介绍了TA标准与其他CDISC基础标准的关系、TA用户指南的一般结构、TA标准开发流程,以及冠心病心绞痛中医药治疗领域数据标准项目开发情况,并讨论开发过程面临的主要困难,旨在向国内用户介绍CDISC的TA数据标准,并为其他中医药TA数据标准的开发提供参考。
Clinical data interchange standards consortium(CDISC) has developed a series of fundamental data standards for organizing and formatting clinical and nonclinical research data to streamline processes in collection, management, analysis, reporting and submission. At present, CDISC standards have been adopted by global regulatory agencies, pharmaceutical and academic communities. To accelerate the development of clinical research data standards for specific disease areas that are important to public health, CDISC began to develop therapeutic area(TA) data standards starting from 2012 and since then, more than 20 TA standards have been released. In comparison to fundamental standards, TA standards are less known within the Chinese user community. This article introduced the relationship between TA and fundamental standards, the general structure of a TA user guide(TAUG), the steps required for the development of TA standards and the TCM TA project-angina of coronary artery diseases. In addition, main problems in the process of development are discussed, with the purpose to introduce the CDISC TA standards to the Chinese domestic users and provide a reference for other TCM TA projects.
引文
[1] Clinical Data Interchange Standards Consortium. CDISC Mission&Principles[EB/OL].[2016-09-14].http://www.cdisc.org/about/mission.
[2]吴崇胜,包文俊,王军,等.CDISC标准介绍及在中国的应用[J].药学学报,2015,50(11):1428-1433.
[3]国家食品药品监督管理总局.临床试验数据管理工作技术指南[EB/OL].[2016-08-05].http://www.sda.gov.cn/WS01/CL0087/160961.html.
[4] Clinical Data Interchange Standards Consortium. Therapeutic Areas[EB/OL].[2017-01-05].https://www.cdisc.org/standards/the rapeutic-areas.
[5]ClinicalDataInterchangeStandardsConsortium.Asthma Therapeutic Area User Guide v1.0[EB/OL].[2017-01-05].https://www.cdisc.org/standards/therapeutic-areas/asthma.
[6]ClinicalDataInterchangeStandardsConsortium.Diabetes Therapeutic Area User Guide v1.0[EB/OL].[2017-01-05].https://www.cdisc.org/standards/therapeutic-areas/diabetes.
[7]ClinicalDataInterchangeStandardsConsortium.Bylaws&Policies[EB/OL].[2017-01-05].https://www.cdisc.org/about/bylaws.
[8]陆芳,李庆娜,赵阳,等.中药新药临床研究数据管理应用CDISC标准的初步探讨[J].中国中医药信息杂志,2016,23(1):9-14.
[9]ClinicalData Interchange StandardsConsortium.Controlled Terminology[EB/OL].[2017-01-05].https://www.cdisc.org/standards/semantics/terminology.
[10]国家食品药品监督管理总局.中药、天然药物治疗冠心病心绞痛临床研究技术指导原则[EB/OL].[2016-11-01].http://www.sda.gov.cn/WS01/CL1616/90942.html.
[11] Clinical Data Interchange Standards Consortium. Public Review[EB/OL].[2018-08-29].https://www.cdisc.org/public-review/traditional-c hinese-medicine-coronary-artery-disease-angina-v10.
[12] World Health Organization Regional Office for the Western Pacific. WHO International Standard Terminologies on Traditional MedicineIntheWesternPacificRegion[EB/OL].[2016-11-01].http://www.wpro.who.int/publications/PUB_9789290612483/en/.
[13]全国科学技术名词审定委员会.中医药学名词[M].北京:科学出版社,2005.